Short Duration Treatment of Non-severe Community Acquired Pneumonia

NCT01963442 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 310

Last updated 2017-08-14

No results posted yet for this study

Summary

To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), who responded well to 3 days of beta-lactamin treatment (3GC or A/AC).

Conditions

  • Community Acquired Pneumonia

Interventions

RADIATION

Chest X-ray

at Day 0, Day 30 and relapse

BIOLOGICAL

blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry

DRUG

Augmentin

2 tablets 3 times a day for 5 days from Day 3

DRUG

Placebo (for Augmentin)

2 tablets 3 times a day for 5 days from Day 3

DRUG

Beta-Lactams

administered from Day 0 to Day 3

Sponsors & Collaborators

  • Versailles Hospital

    lead OTHER

Principal Investigators

  • Anne-Claude CREMIEUX, Pr · Central Hospital Raymon Poincaré

  • Marie Christine DOMBRET, Dr · CHU Bichat

  • Matthieu GROH, Dr · CHU Cochin

  • Elizabeth ROUVEIX, Pr · CHU Ambroise Paré

  • Pascale LONGUET, Dr · CH Argenteuil

  • Daniel BENHAMOU, Dr · CHU Rouen

  • Sylvain DIAMANTIS, Dr · Melun Hospital

  • Jean-Emmanuel Kahn, Dr · Foch Hospital

  • Jean-François BOITIAUX, Dr · Pontoise Hospital

  • Jean-Pierre BEDOS, Pr · Central Hospital of Versailles

  • Jêrome PACANOWSKI, Dr · CHU Saint Antoine (Paris)

  • Valérie GARRAIT, Dr · CHI CRETEIL

  • Elena FOIS, Dr · CH Saint Denis

  • Benjamin WYPLOSZ, Pr · CH Bicêtre

  • Véronique DELCEY, Dr · CH Lariboisière

  • Gilles PIALOUX, Dr · CH Tenon

  • Matthieu REVEST, Dr · CHU Rennes Pontchaillou

  • Jean Paul STAHL, Dr · University Hospital, Grenoble

  • Virginie VITRAT, Dr · CH Annecy Genevois

  • Victoire De Lastours, Dr · CH Beaujon

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01963442 on ClinicalTrials.gov